QURE 241220 6.00C (QURE241220C6000) Stock Options, News & Quotes

US OptionsDetailed Quotes

QURE241220C6000

Watchlist

0.70
-0.05-6.67%

15min DelayTrading Nov 29 11:27 ET

0.75High0.70Low

Intraday

5D
Daily

News

UniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy
BenzingaNov 21 07:08 ET
UniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
GlobeNewswireNov 21 07:05 ET
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $12
Moomoo NewsNov 8 10:31 ET · Ratings
UniQure N.V. (NASDAQ:QURE) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Simply Wall StNov 8 05:08 ET
Cantor Fitzgerald Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $28
Moomoo NewsNov 6 13:31 ET · Ratings
Goldman Sachs Maintains UniQure NV(QURE.US) With Hold Rating, Cuts Target Price to $9
Moomoo NewsNov 6 13:31 ET · Ratings

Comments

Trytosaveabit

Nov 21 06:10

Update

$uniQure NV (QURE.US)$ uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
4 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE

Tonyco

Oct 17 10:54

$CuriosityStream (CURI.US)$
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$

Stock_Drift

Oct 4 14:13

Gainer Ticks. 3:12pm EST.10/4/24

$uniQure NV (QURE.US)$ $Apogee Enterprises (APOG.US)$ $Capricor Therapeutics (CAPR.US)$ $noco-noco (NCNC.US)$ $UP Fintech (TIGR.US)$ $JBDI Holdings (JBDI.US)$ $Snail (SNAL.US)$ $Cue Biopharma (CUE.US)$ $Entero Therapeutics (ENTO.US)$ $Power REIT (PW.US)$ $Ford Motor (F.US)$ $Beneficient (BENF.US)$ $Phoenix Motor (PEV.US)$ $Chanson International (CHSN.US)$
📊⚡️📊

Stock_Drift

Sep 23 06:10

$uniQure NV (QURE.US)$

Jaguar8

Sep 23 06:06

NEWS

$uniQure NV (QURE.US)$
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) announced that the U.S. FDA has granted Orphan Drug Designation to AMT-191, their investigational gene therapy for Fabry disease. This follows the dosing of the first patient in a U.S. multi-center, open-label Phase I/IIa trial in August 2024. AMT-191 is a one-time intravenously administered AAV5-based gene therapy targeting the liver to produce G...